Does CERTOLIZUMAB PEGOL Cause Bladder transitional cell carcinoma? 20 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 20 reports of Bladder transitional cell carcinoma have been filed in association with CERTOLIZUMAB PEGOL (Cimzia). This represents 0.0% of all adverse event reports for CERTOLIZUMAB PEGOL.
20
Reports of Bladder transitional cell carcinoma with CERTOLIZUMAB PEGOL
0.0%
of all CERTOLIZUMAB PEGOL reports
0
Deaths
19
Hospitalizations
How Dangerous Is Bladder transitional cell carcinoma From CERTOLIZUMAB PEGOL?
Of the 20 reports, 19 (95.0%) required hospitalization.
Is Bladder transitional cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CERTOLIZUMAB PEGOL. However, 20 reports have been filed with the FAERS database.
What Other Side Effects Does CERTOLIZUMAB PEGOL Cause?
Drug ineffective (23,838)
Rheumatoid arthritis (17,782)
Pain (13,929)
Fatigue (11,438)
Off label use (10,281)
Rash (9,663)
Alopecia (9,111)
Maternal exposure during pregnancy (9,013)
Arthralgia (8,993)
Abdominal discomfort (8,615)
What Other Drugs Cause Bladder transitional cell carcinoma?
PIOGLITAZONE (398)
ADALIMUMAB (96)
METHOTREXATE (95)
RITUXIMAB (74)
TOCILIZUMAB (68)
INFLIXIMAB (63)
SULFASALAZINE (55)
HYDROXYCHLOROQUINE (50)
PREDNISONE (48)
LENALIDOMIDE (42)
Which CERTOLIZUMAB PEGOL Alternatives Have Lower Bladder transitional cell carcinoma Risk?
CERTOLIZUMAB PEGOL vs CERTOPARIN
CERTOLIZUMAB PEGOL vs CETIRIZINE
CERTOLIZUMAB PEGOL vs CETIRIZINE\PSEUDOEPHEDRINE
CERTOLIZUMAB PEGOL vs CETRIMIDE
CERTOLIZUMAB PEGOL vs CETRORELIX